The filing is a procedural amendment to provide pro forma financials for an S-3 registration statement. The massive dilution of legacy holders (2.4%) and deep operating losses of the combined entity are already known from the original merger announcement. Monitor the stockholder vote on the Series C conversion and any subsequent capital raises or clinical milestones for Marea's pipeline.
LSTA drugs
LSTA drug pipeline →Price Chart
How similar events traded
Executive Summary
This 8-K/A (Amendment No. 2) provides unaudited pro forma combined financial statements for Lisata Therapeutics following its acquisition of Marea Therapeutics on September 17, 2026. The pro forma statements show a combined net loss of $81.0 million for the nine months ended September 30, 2026 and $60.8 million for the year ended December 31, 2025, with legacy Lisata stockholders retaining only 2.4% of the combined company on a fully diluted basis. The filing is procedural, supplementing the original 8-K with required pro forma financials for a registration statement.
Key Facts
- Lisata acquired Marea on September 17, 2026 for an estimated purchase price of $377.8 million, consisting of 1,793,129 common shares and 211,365.213 shares of Series C Preferred Stock.
- A concurrent PIPE raised $225.0 million through the sale of 150,867.995 shares of Series C Preferred Stock at $1,491.37 per share.
- Pro forma combined net loss was $81.0 million for the nine months ended September 30, 2026 and $60.8 million for the year ended December 31, 2025.
- Pro forma basic and diluted net loss per share was $7.47 for the nine months ended September 30, 2026 and $5.80 for the year ended December 31, 2025.
- On a fully diluted basis after stockholder approval, former Marea stockholders are expected to hold 59.5%, PIPE investors 38.1%, and legacy Lisata stockholders 2.4% of the combined company.
- The preliminary purchase price allocation includes $292.9 million of in-process research and development (IPR&D) and $64.7 million of goodwill.
- Marea raised $65.0 million in bridge financing via SAFEs prior to the merger, which converted into Marea common stock at $1.45 per share.
Financial Impact
Pro forma combined net loss of $81.0M for 9M 2026 and $60.8M for FY 2025; legacy Lisata stockholders diluted to 2.4% ownership on a fully diluted basis.
Risk Factors
- Legacy Lisata stockholders face extreme dilution to 2.4% of the combined company on a fully diluted basis.
- The combined company reported substantial operating losses ($102.3M for 9M 2026 pro forma) with no near-term revenue prospects.
- The preliminary purchase price allocation is subject to change and could materially affect reported financials.
- The Series C Preferred Stock carries a Cash Settlement Right that could require significant cash outflows if conversion is delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001140361-26-044916 |
| Document: ef20085959_8ka.htm | 0001140361-26-044916 |
| Document: 0001140361-26-044916-index-headers.html | 0001140361-26-044916 |
| Document: 0001140361-26-044916-index.html | 0001140361-26-044916 |
| Document: 0001140361-26-044916.txt | 0001140361-26-044916 |
Track record
21 reports on LSTA
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K/A Neutral 3/10 Viewing Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
- Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
- Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
- Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
- Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
- Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
- Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
- Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers